Promoter pledges 0.83% stake in Sudarshan Pharma Industries

Promoter Mr. Hemal Vasantrai Mehta has pledged 0.83% of the total share capital of Sudarshan Pharma Industries Ltd . The disclosure, submitted to BSE Limited on June 5, 2026, details the encumbrance of shares as per Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Details of the Encumbrance

The transaction involved the creation of a pledge on 20,00,000 shares. The encumbrance was established on June 3, 2026, in favor of Mr. Kirit Ratilal Shah. Prior to this event, the promoter reported no encumbered shares.

Shareholding Pattern

Mr. Hemal Vasantrai Mehta holds a significant stake in the company. The filing outlines his total holdings and the specific percentage of the capital affected by this pledge.

Promoter	Total Shares Held	% of Total Share Capital	% w.r.t Diluted Share Capital
Mr. Hemal Vasantrai Mehta	6,40,21,020	26.60%	26.60%

Breakdown of Pledged Shares

The following table details the specific shares encumbered and the remaining unencumbered holding following the event.

Type of Event	Date of Event	Type of Encumbrance	No. of Shares	% of Total Share Capital	Entity in Favor
Creation	03/06/2026	Pledge	20,00,000	0.83%	Mr. Kirit Ratilal Shah
Balance	-	-	6,20,21,020	25.77%	-

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.94%	-8.18%	+9.07%	+26.88%	+9.03%	+387.03%

Sudarshan Pharma Industries reported a 56.8% rise in net profit to ₹2,198.16 lakh for the financial year ended March 31, 2026, compared to ₹1,402.16 lakh in the previous year. Revenue from operations increased 32.8% to ₹66,749.85 lakh from ₹50,249.34 lakh in FY25, while total income rose to ₹67,590.29 lakh. The board approved the audited standalone financial results on April 30, 2026, with statutory auditors issuing an unmodified review opinion.

The company voluntarily adopted Indian Accounting Standards (Ind AS) with a transition date of April 1, 2024, effective from April 1, 2025. This shift from Indian GAAP required a reconciliation of net profit, which stood at ₹1,402.17 lakh under Ind AS for FY25 compared to ₹1,587.70 lakh under previous GAAP. The adoption impacted metrics such as the amortisation of right-of-use assets and expected credit losses.

Financial Performance

For the year ended March 31, 2026, the company reported a profit before tax of ₹2,866.82 lakh, up from ₹1,880.61 lakh in the prior year. Total expenses for the period increased to ₹64,723.48 lakh from ₹48,386.88 lakh, primarily driven by higher purchases of stock-in-trade and finance costs. Earnings per share (EPS) from continuing operations improved to ₹0.91 basic and ₹0.90 diluted from ₹0.58 in the previous year.

Metric	FY26 (₹ in Lakhs)	FY25 (₹ in Lakhs)
Revenue from operations	66,749.85	50,249.34
Total Income	67,590.29	50,549.22
Total Expenses	64,723.48	48,386.88
Net Profit	2,198.16	1,402.16
Basic EPS	0.91	0.58

Corporate Developments

The Board approved raising funds up to ₹1,500 crore via Foreign Currency Convertible Bonds (FCCBs). Following an Extraordinary General Meeting on August 11, 2025, the company received in-principle approval from BSE Limited to issue FCCBs up to USD 35,000,000. The Reserve Bank of India approved a fresh Loan Registration Number for the fund-raising proposal on March 25, 2026, after a previous attempt did not fructify.

In a strategic expansion, the company entered into a definitive agreement on August 4, 2025, to acquire an operational manufacturing facility in Telangana from Srigen Lifesciences Private Limited for ₹25.50 crore. The facility includes land, building, and plant & machinery. Additionally, the company has received ₹4.68 crore, including interest, towards a legal award of approximately ₹9.19 crore from a Dubai court against Regans International DMCC.